HARMONY BIOSCIENCES HOLDINGS
NASDAQ: HRMY (Harmony Biosciences Holdings, I)
Last update: 2 days ago, 5:37PM35.29
-0.27 (-0.76%)
| Previous Close | 35.56 |
| Open | 35.56 |
| Volume | 199,825 |
| Avg. Volume (3M) | 952,357 |
| Market Cap | 2,032,575,616 |
| Price / Earnings (TTM) | 11.13 |
| Price / Earnings (Forward) | 7.50 |
| Price / Sales | 2.37 |
| Price / Book | 2.30 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 20.50% |
| Operating Margin (TTM) | 30.45% |
| Diluted EPS (TTM) | 2.62 |
| Quarterly Revenue Growth (YOY) | 19.50% |
| Quarterly Earnings Growth (YOY) | 18.90% |
| Total Debt/Equity (MRQ) | 24.63% |
| Current Ratio (MRQ) | 3.67 |
| Operating Cash Flow (TTM) | 222.67 M |
| Levered Free Cash Flow (TTM) | 143.41 M |
| Return on Assets (TTM) | 12.81% |
| Return on Equity (TTM) | 24.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Harmony Biosciences Holdings, I | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.10% |
| % Held by Institutions | 92.80% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 55.00 (HC Wainwright & Co., 55.85%) | Buy |
| Median | 42.00 (19.01%) | |
| Low | 36.00 (Deutsche Bank, 2.01%) | Buy |
| Average | 43.00 (21.85%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 31.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 24 Nov 2025 | 55.00 (55.85%) | Buy | 35.27 |
| 25 Sep 2025 | 55.00 (55.85%) | Buy | 27.04 | |
| Needham | 24 Nov 2025 | 42.00 (19.01%) | Buy | 35.27 |
| 24 Sep 2025 | 41.00 (16.18%) | Buy | 26.76 | |
| Mizuho | 06 Nov 2025 | 39.00 (10.51%) | Buy | 30.94 |
| 25 Sep 2025 | 35.00 (-0.82%) | Buy | 27.04 | |
| UBS | 15 Oct 2025 | 43.00 (21.85%) | Buy | 26.63 |
| Deutsche Bank | 25 Sep 2025 | 36.00 (2.01%) | Buy | 27.04 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Nov 2025 | Announcement | Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation |
| 19 Nov 2025 | Announcement | Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence |
| 18 Nov 2025 | Announcement | Harmony Biosciences to Participate in Upcoming Investor Conferences |
| 04 Nov 2025 | Announcement | Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M |
| 23 Oct 2025 | Announcement | Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance |
| 24 Sep 2025 | Announcement | Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |